Nuveen, LLC T Scan Therapeutics, Inc. Transaction History
Nuveen, LLC
- $315 Billion
- Q1 2025
A detailed history of Nuveen, LLC transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Nuveen, LLC holds 69,962 shares of TCRX stock, worth $99,346. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,962Holding current value
$99,346% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TCRX
# of Institutions
91Shares Held
41.2MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.36MShares$7.61 Million6.28% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$7.1 Million0.71% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$6.34 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.5MShares$4.97 Million0.02% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$4.25 Million0.34% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $26.9M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...